With expanding immunotherapy options available in cancers, particularly diffuse large B-cell lymphoma (DLBCL), new methods for identifying immunotherapy sensitivity for individual patients and cancer subtypes are increasingly important. Evaluation of immunotherapy within ex vivo settings is challenging due to the complexity in conserving tumor heterogeneity and its surrounding tumor microenvironment (TME), limited cell yield from primary samples and technical restrictions in drug sensitivity immuno-phenotyping.
